PT  - JOURNAL ARTICLE
AU  - Zhongrong Miao
AU  - Ligang Song
AU  - David S Liebeskind
AU  - Liping Liu
AU  - Ning Ma
AU  - Yilong Wang
AU  - Dapeng Mo
AU  - Feng Gao
AU  - Xingquan Zhao
AU  - Kehui Dong
AU  - Dong Zhang
AU  - Peiyi Gao
TI  - Outcomes of tailored angioplasty and/or stenting for symptomatic intracranial atherosclerosis: a prospective cohort study after SAMMPRIS
AID  - 10.1136/neurintsurg-2014-011109
DP  - 2015 May 01
TA  - Journal of NeuroInterventional Surgery
PG  - 331--335
VI  - 7
IP  - 5
4099  - http://jnis.bmj.com/content/7/5/331.short
4100  - http://jnis.bmj.com/content/7/5/331.full
SO  - J NeuroIntervent Surg2015 May 01; 7
AB  - Background and purpose High periprocedural complication rate is a key limitation of endovascular treatment of intracranial atherosclerotic disease (ICAD), despite potential risk reduction of recurrent stroke. Taking lessons from the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Arterial Stenosis (SAMMPRIS) trial, targeting a selected patient population, we prospectively evaluated the feasibility and safety of tailored angioplasty and/or stenting for patients with ICAD. Methods From November 2011 to October 2012, 158 patients with symptomatic ICAD caused by hypoperfusion combined with poor collateral flow were consecutively recruited into a prospective single center study. Patients were divided into three groups based on arterial access and lesion morphology: balloon mounted stent group (group BS) for smooth access and Mori A lesion, angioplasty plus self-expanding stent group (group AS) for tortuous access and Mori B or C lesion, and angioplasty group (group AG) for tortuous access and Mori A lesion. The primary endpoints were successful procedure rate and any vascular event within 30 days. Results Overall technical success rate was 96.3% (154/158). There were significant differences in the technical success rate: 89.7% (35/39) in group AG compared with 97.5% (79/81) in group BS and 100% (38/38) in group AS (p=0.042). The 30 day composite stroke, myocardial infarction, or death rate was 4.4% (7/158). Stroke within 30 days occurred in four patients in group BS and in three patients in group AS. Conclusions Individualized treatment of ICAD using tailored devices according to arterial access and lesion morphology was feasible and safe in symptomatic patients caused by hypoperfusion with poor collateral flow.